Overview

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin Lispro
Insulin, Globin Zinc
Insulin, Long-Acting